

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION N). F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/763,210 10/16/2001		10/16/2001	Shian-Jiun Shih	A2922AUS	2753
5487	7590	06/13/2006		EXAMINER	
ROSS J.	OEHLER		EPPS FORD, JANET L		
	AVENTSI J JTE 202-206		ART UNIT	PAPER NUMBER	
	DE: D303A		1633		
BRIDGEV	WATER, N.	08807	DATE MAILED: 06/13/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

-			Application	n No.	Applicant(s)					
			09/763,210)	SHIH ET AL.					
Offic		Action Summary	Examiner		Art Unit					
			Janet L. Ep	ps-Ford	1633					
The MAILING DATE of this communication appears on the c v r she t with the correspondence address Period for Reply										
WHIC - Exten after 5 - If NO - Failur Any re	CHEVER IS asions of time m SIX (6) MONTH period for reply re to reply within eply received b	STATUTORY PERIOD FOR REPLY LONGER, FROM THE MAILING DA ay be available under the provisions of 37 CFR 1.13 is from the mailing date of this communication. is specified above, the maximum statutory period we the set or extended period for reply will, by statute, at the Office later than three months after the mailing djustment. See 37 CFR 1.704(b).	ATE OF THI 36(a). In no ever vill apply and will cause the applic	S COMMUNICATION tt, however, may a reply be time expire SIX (6) MONTHS from to attion to become ABANDONEI	I. lely filed the mailing date of this c (35 U.S.C. § 133).					
Status										
2a)⊠ 3)□	This action Since this	e to communication(s) filed on <u>24 Mar</u> is FINAL . 2b) This application is in condition for allowar accordance with the practice under E	action is no	or formal matters, pro		e merits is				
Disp sitio	on of Clair	ms								
5)□ 6)⊠ 7)□	 4) Claim(s) 3-5,7-13,18,22-24,26,27 and 34-38 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 3-5, 7-13, 18, 22-24, 26-27, and 34-38 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. 									
Application	on Papers									
10) 🔲 🗆	The drawin Applicant m Replaceme	cation is objected to by the Examiner g(s) filed on is/are: a) access ay not request that any objection to the control drawing sheet(s) including the correction declaration is objected to by the Example 2.	epted or b) drawing(s) be ion is require	held in abeyance. See d if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 C					
Priority u	nder 35 U	S.C. § 119								
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 										
2) Notice 3) Inform	e of Reference e of Draftsper	es Cited (PTO-892) son's Patent Drawing Review (PTO-948) ure Statement(s) (PTO-1449 or PTO/SB/08) ate		4) Interview Summary (Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:	te	O-152)				

DETAILED ACTION

1. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Response to Amendment

2. The rejection of claims 1, 3-5, 7-13, 18, 22-24, 26-31, and 34 under 35 U.S.C. 112, second paragraph, is withdrawn in response to Applicant's amendment.

New grounds of Rejection

Claim Rejections - 35 USC § 112

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 3-5, 7-13, 18, 22-24, 26-27, and 34-38 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. (New Matter).

Claim 34, and those claims dependent therefrom, claims 3-5, 7-13, 18, 22-24, 26-27, and 35-38, recite the following phrase: "stored at a temperature greater than about 4°C for at least about 3 months." However, there is no clear support for these open-ended ranges wherein applicants have support for storage temperatures that encompass all temperatures above 4°C, other than +20°C, and for all periods of time beyond 3 months, other than a maximum of 8.5 months to 1 year, wherein applicants

Application/Control Number: 09/763,210

Art Unit: 1633

were able to enhance the titer of or preserve recombinant adenovirus vectors or

Page 3

particles. Applicant's amendment is considered new matter since the specification as

filed does not provide adequate support for the full scope of the newly added limitations

to the claims.

Response to Arguments

Claim Rejections - 35 USC § 103

5. Claims 7-13, 22-24, 26, and 34 remain rejected and new claims 35-38 are

rejected under 35 U.S.C. § 103(a) as being unpatentable over Crespo in view of Engler

et al. (US 2003/021 1598); and claims 3-5, 7-13, 18, 22-24, and 26-27 remain rejected

and claims 34-38 are rejected under 35 USC 103(a) as being unpatentable over Crespo

in view of Engler et al. (US 2003/021 1598), and further in view of Rolland et al. and

Sene, for the reasons of record.

6. Applicant's arguments filed 3-24-06 have been fully considered but they are not

persuasive. Applicants traverse the instant rejection on the grounds that neither Crespo

nor Engler et al. disclose the step of storing said recombinant adenovirus vectors or

particles at a temperature greater than about 4°C. Moreover, Applicants argue that the

disclosure of Crespo et al. that teaches temperatures of about 37°C, represent thawing

conditions, and does not represent storage conditions of greater than about 4°C, as

recited in the instant claims. Contrary to Applicant's assertions, the specification as filed,

at page 34, lines 3-7, recites:

This Example summarizes the efficiency of a formulation comprising 10mM Tris-HCl + 5%

HSA + 5% sucrose + 150mM NaCl + 2mM MgCl₂, pH 8.4 (Formulation 19) to preserve adenoviral

i vectors at four storage temperatures for 0 (2 days), 1.5, 3.5, and 8.5 months. This study was designed to determine optimal formulation of an adenovirus vector to achieve at least one (1) year stability when

stored frozen at -20°C, or as a liquid at +4°C or +20°C storage temperatures.

Specifically, it states that conditions that are greater than 4°C (i.e. +4°C) or +20°C, represent wherein the optimal formulation is in a liquid form, i.e. in a *thawed* form. Therefore, the teachings of Crespo et al., which encompasses, temperatures that fall within the range of *greater* than about 4°C (wherein there is no upper limit), actually meet the limitations of the claimed invention.

Moreover, Applicants suggest evidence of unexpected results as evidence of the non-obviousness of the claimed invention, however there is no support as stated above, in the specification as filed, wherein Applicants have demonstrated unexpected results for compositions useful for preserving adenovirus at *any* temperature above 4°C, and for *any* period of time.

Absent evidence to the contrary, one of ordinary skill in the art would have been motivated and would have had a reasonable expectation of success in employing the Tris-HCl/NaCl/ MgCl₂)/HSA based solution (produced by the combination of Crespo and Engler et al.) in preserving and storing adenoviral vectors because each of the ingredients employed in the solution is expected to help stabilize and/or enhance the intended function of the adenoviral vectors, as taught by the combination of the references as a whole.

Conclusion

7. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Art Unit: 1633

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet L. Epps-Ford whose telephone number is 571-272-0757. The examiner can normally be reached on M-F, 10:00 AM through 6:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dave T. Nguyen can be reached on 571-272-0731. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000-

Primary Examiner

Janet L. Epps/Ford, Ph. 40

Art Unit 1633